Showing results (1-10 of 70) with videos related to
Sort By:
Pageof 7
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|June 3, 2021
[Quality Control and Quality Assurance for the Intermediate Zone between Food and Drug: Rational Use of Such Products and the Need to Modify the Pharmacy Education]Kiichiro TsutaniBMC Research Notes|July 1, 2011
How Can the Evidence from Global Large-scale Clinical Trials for Cardiovascular Diseases be Improved?Hiroshi Sawata, Kiichiro TsutaniYakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|December 27, 2013
[Historical changes in the list of plasma fractionation products placed on the WHO Model List of Essential Medicines]Yuichiro Sakagami, Kiichiro TsutaniYakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|June 4, 2008
[Regulatory sciences in herbal medicines and dietary supplements]Kiichiro Tsutani, Hiroki TakumaBMC Medical Research Methodology|November 3, 2011
Funding and infrastructure among large-scale clinical trials examining cardiovascular diseases in Japan: evidence from a questionnaire surveyHiroshi Sawata, Kiichiro TsutaniYakushigaku Zasshi|March 25, 2015
[The history of regulatory system for plasma fractionation products in the United States]Manabu Fukuzawa, Kiichiro TsutaniZhong Xi Yi Jie He Xue Bao = Journal of Chinese Integrative Medicine|October 22, 2011
Duplicate publication cases in the field of Kampo (Japanese herbal medicine) in JapanMasamichi Kitagawa, Kiichiro TsutaniEuropean Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|September 22, 2007
Approval of new biopharmaceuticals 1999-2006: comparison of the US, EU and Japan situationsKaori Tsuji, Kiichiro TsutaniTrials|April 16, 2011
Limited accessibility to designs and results of Japanese large-scale clinical trials for cardiovascular diseasesHiroshi Sawata, Kenji Ueshima, Kiichiro TsutaniNihon Rinsho. Japanese Journal of Clinical Medicine|October 20, 2010
[Pharmacoeconomics of molecular target drugs in Japan]Kiichiro Tsutani, Ataru Igarashi, Takeru ShiroiwaPageof 7